News
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
These are the first clinical study results for the drug in a large population of patients with darker skin tones ...
Regeneron Pharmaceuticals Inc. (NASDAQ ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 ...
6d
Clinical Trials Arena on MSNRegeneron and Sanofi’s dupilumab shows promise in AD trialRegeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).
Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...
Regeneron Pharmaceuticals ... It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced ...
Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results